Colleen Silk on Novo Nordisk Performance at ASH25
Colleen Silk, Corporate Vice President, Rare Disease at Novo Nordisk, shared on LinkedIn:
”I’m so proud to have attended the 2025 ASH Annual Meeting in Orlando over the weekend alongside so many talented colleagues from our Hemoglobinopathies and Rare Blood Disorders teams.
It was so inspiring to see the dedication, expertise, and collaboration that went into making this meeting such a success for Novo Nordisk.
In addition to the great work that went into our exhibit booth and many poster and oral presentations, ASH was an invaluable opportunity to engage directly with the hematology community.
We had meaningful conversations with KOLs where we shared the science and our vision for expanding treatment options for people living with rare blood disorders and sickle cell disease.
These dialogues will help shape our path forward and accelerate the impact of our future portfolio.
A huge thank you to everyone who worked so hard to bring this to life.
From our US Field and Home Office cross-functional teams and our partners in Global, everyone contributed to making the congress truly outstanding.
I’m excited for what lies ahead for the Rare Disease team at Novo Nordisk as we continue to educate with the goal of bringing innovative therapies to patients who need them most.”
Stay updated with Hemostasis Today.
-
Jun 23, 2026, 23:05Rounak Dubey: ISBT Academy Session on Agentic AI
-
Jun 23, 2026, 22:59Mohammed Maher Babiker: Don’t Let EDTA Fool You – When ‘Low Platelets’ aren’t Really Low
-
Jun 23, 2026, 22:49Giovanni Merlino: Why Does Stress Hyperglycemia Worsen Stroke Outcomes?
-
Jun 23, 2026, 22:41Tareq Abadl: Coombs Test – The Key to Detecting Immune-Mediated Hemolysis
-
Jun 23, 2026, 22:32How WFH Impacted the Bleeding Disorders Community in 2025
-
Jun 23, 2026, 22:03Erin VanDyke: A Journey Through VTE Leadership and Healthcare Transformation
-
Jun 23, 2026, 20:30Aladdin Mohammad: Baseline IgG as a Key Predictor of Hypogammaglobulinaemia in AAV
-
Jun 23, 2026, 19:20Simos Kokkovos: 1st Ever Mobile Stroke Unit in Greece is on its way to Metropolitan Hospital
-
Jun 23, 2026, 18:27Advancing Gene Therapy Research for Glanzmann Thrombasthenia – Glanzmann’s Research Foundation